Novapeutics LLC

Novapeutics LLC is a biopharmaceutical company that was established based on research from the University of Pennsylvania. The company's primary objective is to create a groundbreaking oral treatment that can reverse the effects of diabetes by stimulating the regeneration of insulin-producing beta cells. Their approach involves utilizing small molecule therapeutics to disrupt menin and mixed lineage leukemia (MLL) proteins, which are known as menin inhibitors. These inhibitors help to enhance the natural regeneration of beta cells in diabetes patients. With the support of funding from the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novapeutics has identified promising novel menin inhibitors that will serve as the basis for their drug development efforts.